Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 14:20 save search
FDA Lifts Partial Hold on Arcellx’s Multiple Myeloma Trial After Patient Death
Published: 2023-08-15 (Crawled : 14:20) - biospace.com/
JNJ | News | $144.54 -0.16% 4.9M
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
fda trial
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Published: 2023-07-27 (Crawled : 14:20) - biospace.com/
MRK | $124.9 -0.38% 1.4M
|
Health Technology
|
| O: 0.09%
H: 0.35%
C: -1.84%
pneumococcal vaccine merck trials
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Published: 2023-07-25 (Crawled : 14:20) - globenewswire.com
NYMX | $0.2 -19.68% -23.88% 930K
|
Health Technology
| Email alert
Add to watchlist
cancer treatment trial results
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
Published: 2023-07-19 (Crawled : 14:20) - biospace.com/
SNPX | $4.89 1.88% 9.6K
|
Professional, Scientific, and T...
|
| O: 3.4%
H: 2.13%
C: -6.38%
fda drug sclerosis application trial
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
BSTG 4 | $4.03 67.25% 4.5K
|
Manufacturing
|
| O: 3.36%
H: 11.0%
C: 0.0%
disease trial
Relieve Caregiver Burden, Improve Neurodegenerative Clinical Trials
Published: 2023-05-18 (Crawled : 14:20) - ppdi.com
TMO | News | $542.71 -0.83% 1.2M
|
Health Technology
|
| O: -0.17%
H: 0.74%
C: 0.53%
trials neurodegenerative
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
Published: 2023-05-17 (Crawled : 14:20) - biospace.com/
SKYE | $17.01 -2.02% 40K
|
Transportation and Warehousing
|
| O: 3.45%
H: 3.33%
C: -3.33%
six agonist bioscience trial
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
Published: 2023-05-03 (Crawled : 14:20) - biospace.com/
KPTI | $1.285 -6.88% 890K
|
Health Technology
|
| O: 0.56%
H: 4.86%
C: 1.67%
presentation international study
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Published: 2023-05-01 (Crawled : 14:20) - globenewswire.com
IMMP | News | $2.23 -1.33% 130K
|
Health Technology
|
| O: 1.52%
H: 0.9%
C: 0.9%
sight-005 bavencio approval trial therapy
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
Published: 2023-05-01 (Crawled : 14:20) - globenewswire.com
PRFX 1 d | $0.9109 17K
|
Health Technology
|
| O: 17.2%
H: 8.7%
C: -0.15%
prf-110 positive
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
Published: 2023-04-20 (Crawled : 14:20) - globenewswire.com
ITRM | $1.45 -0.69% 49K
|
Health Technology
|
| O: 4.42%
H: 0.0%
C: -9.32%
trials application therapeutics
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $15.17 0.6% 180K
|
Health Care and Social Assistan...
|
| O: 0.75%
H: 6.59%
C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-04-11 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 2.95%
H: 0.0%
C: -4.66%
xenleta fibrosis trial therapeutics
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-08-11 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 2.74%
H: 10.14%
C: -0.87%
xenleta fibrosis trial therapeutics
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - prnewswire.com
THRX | $4.06 0.49% 0
|
|
| O: -0.62%
H: 11.18%
C: 9.73%
the-630 asco publication ongoing pharmaceuticals meeting trial results
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
GRTX | $0.1787 -9.93% 3.5M
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.18%
disease kidney meeting trial
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
ALLO | $3.555 1.28% 260K
|
Health Technology
|
| O: 0.18%
H: 1.96%
C: -3.21%
allo-501 presentation cell trials meeting therapeutics
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
TGTX | $14.47 4.7% 1.6M
|
Health Technology
|
| O: 0.09%
H: 8.17%
C: -1.19%
briumvi presentation sclerosis trials meeting therapeutics
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeHutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke
Published: 2023-04-17 (Crawled : 14:20) - biospace.com/
XBIT | $7.85 -3.21% 60K
|
Health Technology
|
| O: 4.49%
H: 0.23%
C: -1.08%
candidate stroke trial therapy
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Published: 2023-04-17 (Crawled : 14:20) - biospace.com/
COGT | $6.54 0.15% 330K
|
Health Technology
|
| O: 0.68%
H: 7.45%
C: 5.9%
bezuclastinib pipeline preclinical meeting trial therapy
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.